Abstract
Report Statistics
|
- Publication Date: May 31st 2011
- Total Number of Pages: 46
- Available Formats: Web, PDF and Paper
|
Through its five product groups - Trauma, Spine, Craniomaxillofacial (CMF),
Biomaterials and Power Tools - Synthes Inc. develops and manufactures
instruments, implants and biomaterials for the surgical fixation, correction
and regeneration of the human skeleton and its soft tissues, including both
metallic and osteobiological materials. The group also has a power tools
business.
- Synthes Trauma produces plate and screw systems, intramedullary
nailing systems and external fixation devices that are used for the surgical
treatment of fractures, deformities and tumour diseases of long bones. The
company also produces trauma implants for the shoulder, hand, pelvis, hip,
condyles and foot.
- The Synthes Spine portfolio covers products for the treatment of
degenerative instabilities, fractures, tumours and deformities. The company
offers a full range of solutions for the cervical, thoracic and lumbar spine.
- The company' s CMF systems offer a range of facial trauma, tumour
resection and reconstructive implants and instruments. In August 2009, Synthes
expanded beyond its core CMF business through an agreement with Kensey Nash to
market and distribute the XCM (extra-cellular matrix) porcine dermis product
for soft tissue reconstruction in ventral hernias and head and neck procedures.
- Synthes' Biomaterials include a paste that can be used to fill bony
defects; an implant for young children that resorbs after the body' s bones
have healed; and demineralised human bone that promotes bone healing. In May
2011, Synthes sold the Norian assets of its Biomaterials division to Kensey
Nash.
- Synthes Power Tools offers a range of air- and battery-driven drill
systems, reamers and saws for use in orthopaedics and trauma surgery. In
November 2010, this business was expanded with the acquisition of Anspach,
which provided a complementary high-speed product line to the Synthes power
tools portfolio.
Synthes is the world leader in traumatology, ranks among the top
companies for spinal devices and is in the leading position in the CMF
business.
In 2010, Synthes generated revenues of US$3.7 billion and net earnings
of US$908 million. The company employs more than 11,400 people, mainly in the
US, Switzerland, Germany, Austria and China.
Synthes Inc. is registered in Delaware, US. Its holding company, Synthes GmbH,
is based in Switzerland. Synthes Inc shares of common stock are listed on the
SIX Swiss Exchange and included in the Swiss Market Index (SMI) and are traded
on SWX Europe, the SIX Swiss Exchange' s blue chip trading platform in London.
As of 31st December 2010, Dr h.c. mult. Hansjorg Wyss, Chairman of Synthes
Inc, and Wyss family trusts held 40 and 8% of the company' s shares,
respectively.
In April 2011, Synthes entered into a definitive agreement to be
acquired by Johnson & Johnson for US$21.3 billion. At the time of the
announcement, Synthes' Board of Directors approved the transaction and Dr Wyss
and related parties agreed to vote shares representing not less than 33% of
Synthes common stock in support of the transaction.
Under the terms of the purchase agreement, Synthes will be merged with
Johnson & Johnson' s DePuy franchise, which offers a broad range of products
across the orthopaedic and neurological care markets. The combined
Synthes/DePuy business will represent the largest component within Johnson &
Johnson' s Medical Devices and Diagnostics segment.
Reflecting the complex nature of the deal, Johnson & Johnson expects the
acquisition to be completed during the first half of 2012. Antitrust approval
is needed in the US and in Europe, as well as in certain other jurisdictions.
Since Synthes is technically incorporated outside of Switzerland, Swiss
takeover regulations do not apply to the merger. However, the takeover, which
would make DePuy the world' s largest orthopaedic group, could still flounder
if antitrust regulators find the combination would be a too dominant force in
orthopaedics. While the consensus in media quarters is that Johnson & Johnson
will unlikely face any competition from rival bidders for Synthes, regulators
may still force through the sale of some areas of the combined business.
This company report provides
Overview
- Key contact information
- Introduction to the company and its current activities
- Summary of its financial performance
- Who are the company' s major competitors?
- Key recent events in an “at a glance” format
Financial Review
- Current year and annual financial data, including revenue breakdowns by
product area and geographic region (if available)
- Table providing in-depth five-year financial analysis
- Employee data, including breakdown by company division and geographic
location
Strategic Focus
Investigates the company' s aims and its areas of focus
Products
Core product areas, key brands, product approvals and launches
Research and Development
- How much has been invested in R&D?
- Where is the research based?
- What alliances and agreements does the company have and with whom?
Manufacturing and Distribution
- Identifying the company' s manufacturing locations
- Sales and marketing facilities
Agreements
- With whom has the company reached agreements and what do they involve?
- Key contracts awarded
Mergers, Acquisitions, Minority Investments and Divestments
Litigation
Key Corporate Events
Table of Contents
OVERVIEW
FINANCIAL REVIEW
- First Quarter 2011 Financial Results
- 2010 Financial Results
- Five-Year Financial Data
- Employees
STRATEGIC FOCUS
- North America
- Europe, Middle East and Africa (EMEA)
- Asia Pacific
- Latin America
- Joining Johnson & Johnson
PRODUCTS
- Trauma
- Spine
- CMF
- Biomaterials
- Power Tools
- Veterinary
RESEARCH AND DEVELOPMENT
- R&D Establishments
- R&D Investment
- AO Foundation
- Research Agreements
- Studies and Trials
- Trials Comparing Cervical Arthroplasty and ACDF
MANUFACTURING
AGREEMENTS
- Materialise
- Kensey Nash
- Smith & Nephew
- Osteotech
- Fastenetix
- Musculoskeletal Transplant Foundation (MTF)
MERGERS AND ACQUISITIONS
- Anspach
- Innomedic
- N Spine
- AO Foundation - Intellectual Property
- Techron
- Mathys Medizinaltechnik AG
- P2P Minimally Invasive Spine System
- Gelifex
- Spine Solutions
- Norian
MINORITY INVESTMENTS
- Innovative Spinal Technologies
DIVESTITURES
- Norian assets
- Techron' s non-core business
- Medivision
- Prosthetics Business
LITIGATION
- Norfolk County Retirement System
- US Department of Justice and OIG
KEY CORPORATE EVENTS
LIST OF TABLES:
- SUMMARY OPERATING RESULTS
- Recent Key Events
- Synthes - First Quarter 2011 Sales
- Synthes - Annual Financial Results, 2006-2010
- Synthes - Annual Financial Results by Geographic Area, 2006-2010
- Synthes - Five-Year Financial Summary, 2006-2010
- Synthes Employees, 2006-2010
- Synthes Trauma Product Summary
- Synthes Spine Product Summary
- Synthes CMF Product Summary
- Synthes Biomaterials Product Summary
- Synthes Power Tools Summary
- Agreements Summary
- Mergers and Acquisitions Summary
LIST OF CHARTS:
- Synthes - Annual Sales and Operating Income, 2006-2010
- Synthes - Annual Sales by Geographic Area, 2006-2010
- Synthes - 2010 Employees by Geographic Area
利用規約
